Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2019 09:47 ET | Source: Quantum Genomics

Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension

PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
April 26, 2019 08:00 ET | Source: Quantum Genomics

Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation

PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
April 17, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure

PARIS and NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new drug class that...
March 28, 2019 13:00 ET | Source: Quantum Genomics

Quantum Genomics Reports Full-Year 2018 Financial Results

A 2018 fiscal year marked by significant progress in the following research programs:-- Arterial hypertension: highly significant efficacy of firibastat demonstrated in completed Phase IIb trial,...
March 20, 2019 13:00 ET | Source: Quantum Genomics

Quantum Genomics Announces Positive Results from New Preclinical Studies on Firibastat

PARIS and NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company announces positive results from preclinical reproductive...
February 25, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Completes Enrollment in Its Pharmacokinetic Clinical Study of Firibastat

PARIS and NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
February 06, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure

PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
January 31, 2019 13:12 ET | Source: Quantum Genomics

Quantum Genomics Presents its 2019 Corporate Action Plan

PARIS, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...
February 23, 2017 12:00 ET | Source: Quantum Genomics

Quantum Genomics has joined the Pass French Tech program

PARIS and NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical...
October 13, 2016 12:00 ET | Source: Quantum Genomics

Quantum Genomics announces 2016 first-half financial results and first nine months business update

Sound balance sheet: €13.2 M cash and no financial debt at 30 June18-month financial visibilityPARIS and NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 -...